Lymphoma Program to Collaborate with Mayo Clinic in Nationwide, Multi-Instutional Grant on Survivorship in Non-Hodgkin Lymphoma

Last week the Mayo Clinic received an $11 million grant from the National Cancer Institute (NCI) to support research addressing the current and long-term unmet healthcare needs of patients with non-Hodgkin lymphoma. This NCI funded, multi-institutional project is known as the “Lymphoma Epidemiology of Outcomes Cohort Study”. At the Weill Cornell site, Dr. Peter Martin will serve as the Principal Investigator, and Dr. John Leonard will be a participating investigator.

As Principal Investigator at the Weill Cornell site, Dr. Martin, who is the Charles, Lillian, and Betty Neuwirth Clinical Scholar in Oncology, will be overseeing the recruitment of participants and reporting of outcomes. “The LEO Collaboration will be the largest study of it’s kind anywhere in the world and will undoubtedly lead to important, impactful discoveries. We look forward to enrolling participants at Weill Cornell as we seek avenues to increase long-term prognosis and survivorship for those living with NHL,” says Dr. Martin.

Working with participating investigators, Dr. John Leonard and Dr. Giorgio Inghirami (Pathology, Weill Cornell Medical College). “This multi-institutional collaborative study group, supported by the NCI, has a highly productive track record. We are very happy to be a part of it,” says Dr. Leonard.

Look to this space for further information about this study, and other Hodgkin lymphoma related trials. A full listing of our non-Hodgkin lymphoma trials can be found here.

Dr. John Leonard Discusses Use of Lenalidomide + Rituximab in Patients with Recurrent Follicular Lymphoma

In this video clip from OncLive Lymphoma Program Director, John Leonard, MD discusses the combination of lenalidomide and rituximab in patients with recurrent follicular lymphoma.

Clinical Trials or Standard Treatment? Understanding Options for Blood Cancers

On March 18, 2015 Lymphoma Program Director, Dr. John Leonard presented a brief program with the LLS entitled, “Clinical Trials or Standard Treatment? Understanding Options for Blood Cancer“. The program covered:

  • The role of clinical trials in blood cancer treatment
  • How clinical trials are designed.
  • How to determine the best treatment options for patients
  • Talking to your healthcare team about treatment options

An audio recording of the presentation is available along with program slides and and a transcript of the presentation.